IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 7.03
(-0.71%)
SEK 7.03
(-0.71%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 58.03 Million SEK | 7.0% |
| 2022 | 174.24 Million SEK | 50.06% |
| 2021 | 116.11 Million SEK | 26.96% |
| 2020 | 91.45 Million SEK | -4.68% |
| 2019 | 95.94 Million SEK | 29.81% |
| 2018 | 73.91 Million SEK | 33.45% |
| 2017 | 55.38 Million SEK | 19.9% |
| 2016 | 46.19 Million SEK | 67.31% |
| 2015 | 27.61 Million SEK | 90.03% |
| 2014 | 14.53 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 47.87 Million SEK | 32.23% |
| 2024 Q3 | - SEK | -19.79% |
| 2024 Q1 | 36.2 Million SEK | 5.08% |
| 2023 Q2 | 51.74 Million SEK | -13.05% |
| 2023 Q4 | 34.45 Million SEK | -15.42% |
| 2023 FY | 186.44 Million SEK | 7.0% |
| 2023 Q3 | 40.73 Million SEK | -21.27% |
| 2023 Q1 | 59.5 Million SEK | 31.47% |
| 2022 Q3 | 40.42 Million SEK | -19.83% |
| 2022 Q2 | 50.42 Million SEK | 32.25% |
| 2022 Q1 | 38.13 Million SEK | 9.75% |
| 2022 FY | 174.24 Million SEK | 50.06% |
| 2022 Q4 | 45.26 Million SEK | 11.96% |
| 2021 Q2 | 26.52 Million SEK | 32.82% |
| 2021 FY | 116.11 Million SEK | 26.96% |
| 2021 Q4 | 34.74 Million SEK | -0.41% |
| 2021 Q1 | 19.96 Million SEK | 2.8% |
| 2021 Q3 | 34.88 Million SEK | 31.54% |
| 2020 Q2 | 26.1 Million SEK | 36.94% |
| 2020 Q3 | 26.86 Million SEK | 2.93% |
| 2020 Q4 | 19.42 Million SEK | -27.7% |
| 2020 FY | 91.45 Million SEK | -4.68% |
| 2020 Q1 | 19.06 Million SEK | -27.77% |
| 2019 FY | 95.94 Million SEK | 29.81% |
| 2019 Q4 | 26.38 Million SEK | 22.8% |
| 2019 Q3 | 21.48 Million SEK | -29.36% |
| 2019 Q2 | 30.42 Million SEK | 72.38% |
| 2019 Q1 | 17.64 Million SEK | -5.39% |
| 2018 Q1 | 15.85 Million SEK | 12.62% |
| 2018 FY | 73.91 Million SEK | 33.45% |
| 2018 Q4 | 18.65 Million SEK | 17.59% |
| 2018 Q2 | 23.91 Million SEK | 50.88% |
| 2018 Q3 | 15.86 Million SEK | -33.67% |
| 2017 Q1 | 9.93 Million SEK | -32.01% |
| 2017 Q2 | 10.64 Million SEK | 7.19% |
| 2017 Q3 | 20.73 Million SEK | 94.78% |
| 2017 Q4 | 14.07 Million SEK | -32.12% |
| 2017 FY | 55.38 Million SEK | 19.9% |
| 2016 Q1 | 14.03 Million SEK | 0.0% |
| 2016 FY | 46.19 Million SEK | 67.31% |
| 2016 Q3 | 10.7 Million SEK | 56.23% |
| 2016 Q2 | 6.85 Million SEK | -51.17% |
| 2016 Q4 | 14.6 Million SEK | 36.46% |
| 2015 FY | 27.61 Million SEK | 90.03% |
| 2014 FY | 14.53 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 96.168% |
| AcouSort AB (publ) | 25.87 Million SEK | -124.266% |
| Active Biotech AB (publ) | 44.8 Million SEK | -29.507% |
| Alzinova AB (publ) | 36.39 Million SEK | -59.443% |
| Amniotics AB (publ) | 29.07 Million SEK | -99.611% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -296.035% |
| BioArctic AB (publ) | 89.62 Million SEK | 35.253% |
| Camurus AB (publ) | 1.05 Billion SEK | 94.524% |
| Cantargia AB (publ) | 290.01 Million SEK | 79.99% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -165.042% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -104.866% |
| Genovis AB (publ.) | 88.19 Million SEK | 34.203% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 49.57% |
| Mendus AB (publ) | 129.13 Million SEK | 55.062% |
| Kancera AB (publ) | 63.07 Million SEK | 8.0% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -951.477% |
| LIDDS AB (publ) | 27.75 Million SEK | -109.106% |
| Lipum AB (publ) | 37.3 Million SEK | -55.55% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -699.986% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 57.303% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -253.826% |
| NextCell Pharma AB | -576.01 Thousand SEK | 10174.494% |
| OncoZenge AB (publ) | 15.9 Million SEK | -264.86% |
| Saniona AB (publ) | 1.07 Million SEK | -5288.208% |
| Simris Alg AB (publ) | 38.64 Million SEK | -50.176% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 81.95% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 83.773% |
| Xintela AB (publ) | 57.31 Million SEK | -1.247% |
| Ziccum AB (publ) | 27.87 Million SEK | -108.161% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -698.445% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 68.068% |
| CombiGene AB (publ) | 44.14 Million SEK | -31.458% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 59.415% |
| Intervacc AB (publ) | 79.78 Million SEK | 27.266% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 81.103% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -36.121% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -228.174% |
| Corline Biomedical AB | 30.16 Million SEK | -92.359% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 30.225% |
| Aptahem AB (publ) | 10.01 Million SEK | -479.56% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 56.916% |
| Fluicell AB (publ) | 28.61 Million SEK | -102.785% |
| Biovica International AB (publ) | 133.72 Million SEK | 56.603% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -193.234% |
| Abliva AB (publ) | 27.86 Million SEK | -108.25% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 70.01% |
| 2cureX AB (publ) | 36.51 Million SEK | -58.911% |
| I-Tech AB | 40.14 Million SEK | -44.543% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 93.248% |
| Cyxone AB (publ) | 28.21 Million SEK | -105.682% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 46.94% |
| Biosergen AB | 26.8 Million SEK | -116.461% |
| Nanologica AB (publ) | 69.88 Million SEK | 16.965% |
| SynAct Pharma AB | 224.49 Million SEK | 74.151% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -31.363% |
| BioInvent International AB (publ) | 441.4 Million SEK | 86.853% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -142.257% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 79.972% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -638.659% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 47.679% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -294.769% |